Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases

Expert Opinion on Therapeutic Targets

Volumn 22, Issue 6, 2018, Pages 487-502

  Rostamzadeh, Davood ^a,b   Kazemi, Tohid ^b   Amirghofran, Zahra ^c,d   Shabani, Mahdi ^e,f  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

autoimmune diseases; B cell; FCRL; immunotherapy approaches; infectious diseases; malignancies; signaling pathways

Indexed keywords

B CELL ANTIGEN RECEPTOR; FC RECEPTOR LIKE PROTEIN; LIGAND; PROTEIN; RECEPTOR; UNCLASSIFIED DRUG; FC RECEPTOR; FREB PROTEIN, HUMAN;

AUTOIMMUNITY; B LYMPHOCYTE; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION; MALIGNANT NEOPLASM; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COMMUNICABLE DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; B-LYMPHOCYTES; COMMUNICABLE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, FC; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 85048590319     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2018.1472768     Document Type: Review

References (111)

1. Davis RS., Fc receptor-like molecules. Annu Rev Immunol. 2007;25:525–560.
2. Davis RS, Wang YH, Kubagawa H, et al. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A. 2001;98(17):9772–9777.
3. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14(3):277–289.
4. Guselnikov SV, Ershova SA, Mechetina LV, et al. A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1. Immunogenetics. 2002;54(2):87–95.
5. Xu MJ, Zhao R, Zhao ZJ., Molecular cloning and characterization of SPAP1, an inhibitory receptor. Biochem Biophys Res Commun. 2001;280(3):768–775.
6. Nakayama Y, Weissman SM, Bothwell AL. BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun. 2001;285(3):830–837.
7. Maltais LJ, Lovering RC, Taranin AV, et al. New nomenclature for Fc receptor-like molecules. Nat Immunol. 2006;7(5):431–432.
8. Engel P, Boumsell L, Balderas R, et al. CD nomenclature 2015: human leukocyte differentiation antigen workshops as a driving force in immunology. J Immunol. 2015;195(10):4555–4563.
9. Ehrhardt GR, Leu CM, Zhang S, et al. Fc receptor-like proteins (FCRL): immunomodulators of B cell function. Adv Exp Med Biol. 2007;596:155–162.
10. Davis RS, Dennis G, Jr., Odom MR, et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev. 2002;190:123–136.
11. Davis RS, Ehrhardt GR, Leu CM, et al. An extended family of Fc receptor relatives. Eur J Immunol. 2005;35(3):674–680.
12. Kulemzin SV, Zamoshnikova AY, Yurchenko MY, et al. FCRL6 receptor: expression and associated proteins. Immunol Lett. 2011;134(2):174–182.
13. Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, et al. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer. 2008;123(9):2113–2119.
14. Kazemi T, Asgarian-Omran H, Memarian A, et al. Low representation of Fc receptor-like 1-5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia. Cancer Immunol Immunother. 2009;58(6):989–996.
15. Wang K, Pei H, Huang B, et al. Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Braz J Med Biol Res. 2012;45(12):1112–1118.
16. Portugal S, Tipton CM, Sohn H, et al. Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife. 2015;4.
17. Muellenbeck MF, Ueberheide B, Amulic B, et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med. 2013;210(2):389–399.
18. Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117(20):5425–5437.
19. Rostamzadeh D, Dabbaghmanesh MH, Shabani M, et al. Expression profile of human fc receptor-like 1, 2, and 4 molecules in peripheral blood mononuclear cells of patients with Hashimoto’s thyroiditis and Graves’ disease. Horm Metab Res. 2015;47(9):693–698.
20. Yeo L, Lom H, Juarez M, et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis. 2015;74(5):928–935.
21. Baranov KO, Volkova O, Mechetina LV, et al. [Expression of human B-cell specific receptor FCRL1 in normal individuals and in patients with autoimmune diseases]. Mol Biol (Mosk). 2012;46(3):500–507.
22. Simmonds MJ, Heward JM, Carr-Smith J, et al. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves’ disease. J Clin Endocrinol Metab. 2006;91(3):1056–1061.
23. Zeng Z, Duan Z, Zhang T, et al. Association of FCRL4 polymorphisms on disease susceptibility and severity of ankylosing spondylitis in Chinese Han population. Clin Rheumatol. 2012;31(10):1449–1454.
24. Matesanz F, Fernandez O, Milne RL, et al. The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis. J Neuroimmunol. 2008;195(1–2):146–150.
25. Begovich AB, Chang M, Schrodi SJ. Meta-analysis evidence of a differential risk of the FCRL3-169T–>C polymorphism in white and East Asian rheumatoid arthritis patients. Arthritis Rheum. 2007;56(9):3168–3171.
26. Golmoghaddam H, Amirghofran Z, Aflaki E, et al. Association of FCRL3 genotypes with susceptibility of Iranian patients to rheumatoid arthritis. Immunol Invest. 2013;42(4):296–306.
27. Aslanian-Kalkhoran L, Elieh-Ali-Komi D, Sadeghi-Shabestari M, et al. Investigation of Fc receptor-like 3 (fcrl-3) gene polymorphism (rs7528684) with susceptibility to allergic asthma in Iranian north-western Azeri population. Clin Lab. 2017;63(7):1301–1305.
28. Ise T, Maeda H, Santora K, et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res. 2005;11(1):87–96.
29. Ise T, Nagata S, Kreitman RJ, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007;21(1):169–174.
30. Falini B, Agostinelli C, Bigerna B, et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61(5):930–941.
31. Li FJ, Ding S, Pan J, et al. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood. 2008;112(1):179–187.
32. Polson AG, Zheng B, Elkins K, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006;18(9):1363–1373.
33. Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol. 2012;188(10):4741–4745.
34. Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol. 2012;188(10):4741–4745.
35. Franco A, Damdinsuren B, Ise T, et al. Human Fc receptor–like 5 binds intact igg via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190(11):5739–5746.
36. Campbell JA, Davis RS, Lilly LM, et al. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010;185(1):28–32.
37. Schreeder DM, Cannon JP, Wu J, et al. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol. 2010;185(1):23–27.
38. Ehrhardt GR, Cooper MD. Immunoregulatory roles for Fc receptor-like molecules. Curr Top Microbiol Immunol. 2011;350:89–104.
39. Miller I, Hatzivassiliou G, Cattoretti G, et al. IRTAs: a new family of immunoglobulin like receptors differentially expressed in B cells. Blood. 2002;99(8):2662–2669.
40. Davis RS, Stephan RP, Chen CC, et al. Differential B cell expression of mouse Fc receptor homologs. Int Immunol. 2004;16(9):1343–1353.
41. Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol. 2003;4(1):19–24.
42. Kulemzin S, Chikaev N, Volkova O, et al. Characterization of human FCRLA isoforms. Immunol Lett. 2013;152(2):153–158.
43. Leu CM, Davis RS, Gartland LA, et al. FcRH1: an activation coreceptor on human B cells. Blood. 2005;105(3):1121–1126.
44. Won WJ, Foote JB, Odom MR, et al. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol. 2006;177(10):6815–6823.
45. Li FJ, Schreeder DM, Li R, et al. FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation. Eur J Immunol. 2013;43(11):2980–2992.
46. Nagata S, Ise T, Pastan I. Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J Immunol. 2009;182(12):7518–7526.
47. Swainson LA, Mold JE, Bajpai UD, et al. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1. J Immunol. 2010;184(7):3639–3647.
48. Bin Dhuban K, d’Hennezel E, Nashi E, et al. Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells. J Immunol. 2015;194(8):3687–3696.
49. Ehrhardt GR, Hsu JT, Gartland L, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med. 2005;202(6):783–791.
50. Ehrhardt GR, Hijikata A, Kitamura H, et al. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med. 2008;205(8):1807–1817.
51. Falini B, Tiacci E, Pucciarini A, et al. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood. 2003;102(10):3684–3692.
52. Ershova SA, Naiakshin AM, Mechetina LV, et al. [Expression patterns of the human and mouse IFGP family genes]. Mol Biol (Mosk). 2005;39(5):776–785.
53. Wilson TJ, Presti RM, Tassi I, et al. FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection. Blood. 2007;109(9):3786–3793.
54. Schreeder DM, Pan J, Li FJ, et al. FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. Eur J Immunol. 2008;38(11):3159–3166.
55. Ehrhardt GR, Davis RS, Hsu JT, et al. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A. 2003;100(23):13489–13494.
56. Franco A, Damdinsuren B, Ise T, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190(11):5739–5746.
57. Campbell JA, Davis RS, Lilly LM, et al. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010;185(1):28–32.
58. Fang M, Lanier LL, Sigal LJ. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 2008;4(2):e30.
59. Schreeder DM, Cannon JP, Wu J, et al. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol. 2010;185(1):23–27.
60. Jackson TA, Haga CL, Ehrhardt GR, et al. FcR-like 2 inhibition of B cell receptor-mediated activation of B cells. J Immunol. 2010;185(12):7405–7412.
61. Shabani M, Bayat AA, Jeddi-Tehrani M, et al. Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling. Immunology. 2014;143(3):341–353.
62. Kochi Y, Myouzen K, Yamada R, et al. FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell receptor-mediated signaling. J Immunol. 2009;183(9):5502–5510.
63. Haga CL, Ehrhardt GR, Boohaker RJ, et al. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U S A. 2007;104(23):9770–9775.
64. Shabani M, Hemmati S, Hadavi R, et al. Optimization of gene transfection in murine myeloma cell lines using different transfection reagents. Avicenna J Med Biotechnol. 2010;2(3):123–130.
65. Sohn HW, Krueger PD, Davis RS, et al. FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood. 2011;118(24):6332–6341.
66. Liu Y, Bezverbnaya K, Zhao T, et al. Involvement of the HCK and FGR src-family kinases in FCRL4-mediated immune regulation. J Immunol. 2015;194(12):5851–5860.
67. Zhu Z, Li R, Li H, et al. FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. Proc Natl Acad Sci U S A. 2013;110(14):E1282–1290.
68. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298(5601):2199–2202.
69. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180(2):800–808.
70. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797–1805.
71. Weiss GE, Crompton PD, Li S, et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol. 2009;183(3):2176–2182.
72. Dement-Brown J, Cs N, Ise T, et al. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. J Leukoc Biol. 2012;91(1):59–67.
73. Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol. 2004;165(1):71–81.
74. Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren’s syndrome-associated lymphoproliferation. Arthritis Rheum. 2013;65(4):1085–1096.
75. Khanzadeh A, Habibagahi Z, Hosseini A, et al. Investigation of the human FCRL1, 2, and 4 gene expressions in patients with rheumatoid arthritis. Rheumatol Int. 2016;36(8):1149–1156.
76. Bajpai UD, Swainson LA, Mold JE, et al. A functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64(8):2451–2459.
77. Kochi Y, Yamada R, Suzuki A, et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet. 2005;37(5):478–485.
78. Amara K, Clay E, Yeo L, et al. B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis. J Autoimmun. 2017;81:34-43.
79. Haacke EA, Bootsma H, Spijkervet FK, et al. FcRL4+ B-cells in salivary glands of primary Sjogren’s syndrome patients. J Autoimmun. 2017;81:90–98.
80. Du X, Nagata S, Ise T, et al. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood. 2008;111(1):338–343.
81. Mohan J, Dement-Brown J, Maier S, et al. Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1. Blood. 2006;107(11):4433–4439.
82. Terrier B, Nagata S, Ise T, et al. CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheumatol. 2014;66(2):433–443.
83. Sullivan RT, Kim CC, Fontana MF, et al. FCRL5 delineates functionally impaired memory b cells associated with Plasmodium falciparum exposure. PLoS Pathog. 2015;11(5):e1004894.
84. Doi H, Tanoue S, Kaplan DE. Peripheral CD27-CD21- B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis. Clin Immunol. 2014;150(2):184–191.
85. Kardava L, Moir S, Wang W, et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest. 2011;121(7):2614–2624.
86. Jelicic K, Cimbro R, Nawaz F, et al. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol. 2013;14(12):1256–1265.
87. Mavilio D, Lombardo G, Kinter A, et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med. 2006;203(10):2339–2350.
88. Anders HJ, Zecher D, Pawar RD, et al. Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Res Ther. 2005;7(5):215–224.
89. Marrack P, Kappler J, Kotzin BL. Auto immune disease: why and where it occurs. Nat Med. 2001;7(8):899–905.
90. Dai KZ, Harbo HF, Celius EG, et al. The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes Immun. 2001;2(5):263–268.
91. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol. 2003;24(11):595–602.
92. Lin X, Zhang Y, Chen Q. FCRL3 gene polymorphisms as risk factors for rheumatoid arthritis. Hum Immunol. 2016;77(2):223–229.
93. Yuan M, Wei L, Zhou R, et al. Four FCRL3 gene polymorphisms (fcrl3_3, _5, _6, _8) confer susceptibility to multiple sclerosis: results from a case-control study. Mol Neurobiol. 2016;53(3):2029–2035.
94. Martinez A, Mas A, de Las Heras V, et al. FcRL3 and multiple sclerosis pathogenesis: role in autoimmunity? J Neuroimmunol. 2007;189(1–2):132–136.
95. Umemura T, Ota M, Hamano H, et al. Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut. 2006;55(9):1367–1368.
96. Duchatelet S, Caillat-Zucman S, Dubois-Laforgue D, et al. FCRL3-169CT functional polymorphism in type 1 diabetes and autoimmunity traits. Biomed Pharmacother. 2008;62(3):153–157.
97. Mao C, Pan H, Chen Q, et al. Association between Fc receptor-like 3 C169T polymorphism and risk of systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2010;37(1):191–196.
98. Li K, Zhao M, Hou S, et al. Association between polymorphisms of FCRL3, a non-HLA gene, and Behcet’s disease in a Chinese population with ophthalmic manifestations. Mol Vis. 2008;14:2136–2142.
99. Takatori H, Kawashima H, Matsuki A, et al. Helios enhances Treg cell function in cooperation with FoxP3. Arthritis Rheumatol. 2015;67(6):1491–1502.
100. Golding A, Hasni S, Illei G, et al. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2013;65(11):2898–2906.
101. Alexander T, Sattler A, Templin L, et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis. 2013;72(9):1549–1558.
102. Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222–2232.
103. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854.
104. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847.
105. Benedetti D, Perini C, Tissino E, et al. The B-cell receptor signaling inhibitor molecules CD305 and CD307b are markers of favorable prognosis in chronic lymphocytic leukemia with both mutated and unmutated IGHV gene status. Am Hematol. Blood. 2016;128(22):4358.
106. Jourdan M, Robert N, Cren M, et al. Characterization of human FCRL4-positive B cells. PLoS One. 2017;12(6):e0179793.
107. Meier UC, Owen RE, Taylor E, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol. 2005;79(19):12365–12374.
108. Terrier B, Joly F, Vazquez T, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol. 2011;187(12):6550–6563.
109. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221–237.
110. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006;177(1):84–91.
111. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559–565.